Atossa Therapeutics is expanding investigational Z-endoxifen research into Duchenne muscular dystrophy, looking beyond muscle loss to broader disease biology. T

Atossa Therapeutics is expanding investigational Z-endoxifen research into Duchenne muscular dystrophy, looking beyond muscle loss to broader disease biology. The move extends a drug better known for breast cancer progress into rare disease pipeline diversification.